HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Correction (v73,p102) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shorvon, S D Articles by van Rijckevorsel, K Search for Related Content PubMed PubMed Citation Articles by Shorvon, S D Articles by van Rijckevorsel, K

A new antiepileptic drug

¹ Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK and National Hospital for Neurology and Neurosurgery London, UK, and the National Neuroscience Institute, Singapore
² Centre Neurologique William Lennox, Université Catholique de Louvain, Ottignies-Louvain La Neuve, Belgium

Correspondence to:
Correspondence to:
Professor S Shorvon, Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK;
s.shorvon@ion.ucl.ac.uk

Keywords: schizophrenia; antipsychotic drugs; risperidone; antisaccade error rate; cognitive function tests

Abbreviations: LEV, levetiracetam; PTZ, pentylenetetrazol; GABA, -aminobutyric acid; GAD, glutamic acid decarboxylase; SUDEP, sudden and unexplained death in epilepsy

Recently a new antiepileptic drug, levetiracetam (LEV), was approved for the add on treatment of partial epilepsy, both in the United States and in Europe. This is of potential importance, because this drug is from a class not previously used in epilepsy, although piracetam, a compound with a structure similar to that of levetiracetam, is useful in myoclonus. Both drugs are pyrrolidone derivatives, a class of drugs of interest for both psychotropic and nootropic applications and potentially as neuroprotectants. Levetiracetam (available under the registered trademark of UCB S.A., Keppra^R) is the S-enantiomer of -ethyl-2-oxo-1-pyrrolidine acetamide (fig 1). Homologues sharing the S configuration include a range of other compounds, some of which also have antiepileptic action.¹ The range and extent of the compounds' activity in experimental models of epilepsy and other conditions varies considerably with minor changes to chemical structure, but the full extent of the range of . . . [Full text of this article]

This article has been cited by other articles:

				A. Trabacca, P. Profice, M. C. Costanza, M. Gesualdi, and M. De Rinaldis Levetiracetam in Nonconvulsive Status Epilepticus in Childhood: A Case Report J Child Neurol, May 1, 2007; 22(5): 639 - 641. [Abstract] [PDF]

				M. Y. Splinter Pharmacokinetic Properties of New Antiepileptic Drugs Journal of Pharmacy Practice, December 1, 2005; 18(6): 444 - 460. [Abstract] [PDF]

				F. Vigevano Topical Review: Levetiracetam in Pediatrics J Child Neurol, February 1, 2005; 20(2): 87 - 93. [Abstract] [PDF]

				T. A. Glauser Integrating clinical trial data into clinical practice Neurology, June 25, 2002; 58(12_suppl_7): S6 - S12. [Full Text]